Skip to content

Evaluation of the therapeutic effect of molnopiravir for patients with Quid 19

Evaluation of the therapeutic effect of molnopiravir for patients with Quid 19

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20150107020592N31
Enrollment
60
Registered
2022-01-09
Start date
2021-12-16
Completion date
Unknown
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid-19. Coronavirus infection, unspecified

Interventions

Intervention group: Patients after evaluation and confirmation of Covid 19 and having entry conditions,Enter the study and then patients are divided into two groups A and B based on simple randomizati

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patient over 18 years With moderate Covid 19 who does not need to be hospitalized.

Exclusion criteria

Exclusion criteria: Patients with critical covid 19 Gastrointestinal ulcer or inability to swallow oral medication Thrombocytopenia (platelets less than 100 thousand) Liver enzymes more than 3 times normal GFR <30 or require dialysis Bradycardia (HR <50) Patient dissatisfaction to enter the study

Design outcomes

Primary

MeasureTime frame
Improve oxygenation. Timepoint: 0,1,2,3,5,7 after treatment with Molnopiravir. Method of measurement: pulse oximeter.;Improve ct scan. Timepoint: Five days after starting treatment with mulnopiravir. Method of measurement: CT scan unit.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Mohammad Reza Hashemian

Shahid Beheshti University of Medical Sciences

iran.criticalcare@yahoo.com+98 912 111 9279

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026